Table 2. Primary and Secondary Outcomes of Included Patients.
| No./total No. (%) | Unadjusted risk difference (95% CI) | Adjusted risk ratio (95% CI)a | Adjusted common odds ratioa,b | P valuec | ||
|---|---|---|---|---|---|---|
| Tenecteplase (n = 263) | Alteplase (n = 257) | |||||
| Primary outcome | ||||||
| mRS score 0-1 at 90-120 d (n = 520) | 86/263 (32.7) | 76/257 (29.6) | 3.1 (−4.8 to 11.1) | 1.15 (0.98 to 1.35) | NA | .08 |
| Secondary clinical outcomes | ||||||
| mRS 0-2 at 90 d at 90-120 d (n = 520) | 129/263 (49.0) | 131/257 (51.0) | −1.9 (−10.5 to 6.7) | 0.98 (0.84 to 1.14) | NA | .78 |
| Actual mRS score at 90-120 d (n = 520), median (IQR) | 3 (1 to 5) | 2 (1 to 5) | NA | NA | 0.91 (0.66 to 1.23) | .53 |
| Return to baseline function (n = 471) | 64 (27.0) | 49 (20.9) | 6.1 (−1.6 to 13.7) | 1.25 (0.90 to 1.73) | NA | .18 |
| Length of hospital stay in days (n = 482), median (IQR) | 6 (3 to 13) | 6 (3 to 13) | NA | 1.11 (0.92 to 1.35) | NA | .26 |
| Secondary procedural Outcomes (in patients undergoing EVT) | ||||||
| First acquisition eTICI score 2b-3 (n = 405)d | 19/206 (9.2) | 21/199 (10.5) | −1.3 (−7.1 to 4.5) | 0.89 (0.37 to 2.12) | NA | .80 |
| First acquisition rAOL 2b-3 (n = 405)d,e | 36/206 (17.5) | 29/199 (14.6) | 2.9 (−4.2 to 10.0) | 1.21 (0.75 to 1.93) | NA | .43 |
| Final eTICI scale score 2b-3 (n = 405)d | 174/206 (84.5) | 177/199 (88.9) | −4.5 (−11.0 to 2.1) | 0.95 (0.89 to 1.02) | NA | .16 |
| Procedural complications (n = 408) | 15/207 (7.2) | 7/201 (3.5) | 3.8 (−0.5 to 8.2) | NA | NA | .49 |
| Vessel perforation, median (IQR) | 7 (3.4) | 2 (1.0) | NA | NA | NA | |
| Intracranial dissection, median (IQR) | 0 | 0 | NA | NA | NA | |
| Extracranial dissection, median (IQR) | 2 (1.0) | 1 (0.5) | NA | NA | NA | |
| Emboli to new territory, median (IQR) | 3 (1.5) | 2 (1.0) | NA | NA | NA | |
| Access site complication, median (IQR) | 3 (1.5) | 2 (1.0) | NA | NA | NA | |
Abbreviations: eTICI, extended Thrombolysis in Cerebral Infarction; EVT, endovascular thrombectomy; mRS, modified Rankin scale; NA, not applicable; rAOL, revised arterial occlusive lesion score.
Clinical outcomes were adjusted for age, sex, baseline stroke severity, occlusion location, and time from stroke symptom onset to needle time as fixed-effects variables and site as a random-effects variable. Procedural outcomes were adjusted for age and occlusion location.
Common odds ratio is the odds ratio for a 1-unit increase in the modified Rankin scale score for tenecteplase vs alteplase.
P value for the adjusted effect size or the unadjusted risk difference if the former was not calculated.
Three patients did not have initial intracranial endovascular thrombectomy images.
Scored as follows: 0, primary occlusive thrombus remains same; 1, debulking of proximal part of the thrombus but without any recanalization; 2a, partial or complete recanalization of the primary thrombus with occlusion in major distal vascular branch; 2b, partial or complete recanalization of the primary thrombus with occlusion in minor distal vascular branch or partial recanalization of the primary thrombus with no thrombus in the vascular tree at or beyond the primary occlusive thrombus; and 3, complete recanalization of the primary occlusive thrombus with no clot in the vascular tree beyond.